Philip Morris International Launches New Pod System in UK

PMI by 2FIRSTS.ai
Aug.07.2024
Philip Morris International Launches New Pod System in UK
Philip Morris International launches Veev One pod system in the UK, priced at £8.99, exceeding other e-cigarette brands.

According to The Grocer on August 6th, Philip Morris International (PMI) has launched a new pod system called Veev One in the UK, priced at £8.99 for a starter kit. The pod system has already been introduced in Italy and the Czech Republic in the past year, and the company claims that Veev One has "outperformed other e-cigarette brands" in the local market, becoming the "top" system of its kind.

 

According to reports, the data indicates that the e-cigarette subcategory market (users inserting disposable nicotine liquid pods into rechargeable devices) has grown by 35% since January of this year.

 

Veev One currently offers 12 flavors of pods, covering three major taste categories: aromatic, cool, and warm. These flavors include watermelon, blueberry, mint blue, blueberry raspberry, strawberry, mango, and tobacco.

 

John Rennie, Commercial Director of Philip Morris International's (PMI) UK and Ireland division, stated:

 

At this pivotal moment of transformation in the e-cigarette industry, we are thrilled to introduce Veev One to the UK market.

 

With the development of the UK market, Veev One, as a premium, responsible, and recyclable e-cigarette, is set to stand out and build on its success in the European market.

 

To complement this launch, Philip Morris International (PMI) has also introduced a recycling program, where customers can return used pods and devices to receive a £5 reward towards their next purchase at the IQOS online store.

 

PMI company stated that Veev One differs from traditional devices with its ceramic heating technology that provides a consistent taste, and is equipped with a low liquid level detection system to prevent the burnt taste that occurs when the e-liquid runs out.

 

Several weeks before the release of this product, Imperial Brands also launched the "new and improved" Blu Barpod system device, which is similar to the Veev One and can deliver up to 1000 puffs per pod. Yawer Rasool, the Consumer Market Director for Imperial Brands in the UK and Ireland, stated:

 

As consumers seek stronger taste experiences, more convenient delivery methods, and competitive prices, we believe that the Blu Bar kit provides important sales opportunities for wholesalers and retailers, and offers a new source of income in light of the upcoming ban on disposable e-cigarettes.

 

In January of this year, the conservative government announced that disposable e-cigarettes would be banned in the UK. These devices are closed and cannot be refilled or recharged. The government highlighted disposable e-cigarettes as a key factor in the sharp rise in underage smoking. According to data from Action on Smoking and Health (ASH), the proportion of 11 to 17-year-olds using disposable e-cigarettes has increased nearly ninefold in the past two years.

 

During this government period, measures have been proposed to restrict flavors aimed specifically at the children's market and to ensure manufacturers produce packaging that is "more modest and visually less appealing." Additionally, the government is focused on regulating the display of e-cigarettes in stores to keep them away from children and products that attract them (such as candy).

 

With the gradual implementation of the ban on disposable devices, major disposable brands such as ElfBar and SKE have designed new products that operate outside of regulations. Despite the inevitable impact of the ban, disposable devices still account for 88% of e-cigarette sales in the UK.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia’s withdrawal of its appeal in a landmark liquid-nicotine case has left a High Court ruling that struck down the 2023 nicotine exemption in force, bringing liquid and gel nicotine used in vaping products back under the Poisons Act 1952. At the same time, the Control of Smoking Products for Public Health Act 2024 continues to provide a regulatory framework for vaping products, creating uncertainty over retail sales, taxation and existing inventory. MPs are calling for nicotine vape sales and excise collection to stop, including refunds of more than RM354 million collected since 2023, while industry and consumer groups are asking the government to clarify the current legal position.
Sep.04
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22